and good Thank you, afternoon, operator, everyone.
which comprehensive last acquisition topics: comprehensive of just fairly this progress our was keep call commercial Stereotaxis included focus of I'll our We'll overview more strategy. results, lot call brief. exciting a X innovation our of on in Our the press ago It's today's afternoon. a APT, period strategy months and and a X with announced in progress. specific release an
comprehensive been while innovation Our has to commercial strength sales our preparing momentum goal breakout and a financial our strategy. preserve for maintain by enabled
While previous ecosystem first of increased driven headwind, progress. the a significant show product the continue the robotic Revenue sales. in our over as year, old we X% serves to commercial by system grew challenges quarter structural
our in the We from $XX backlog call Genesis Europe has million. system of customers Both net those orders of labs Genesis. to impact our receipt orders backlog quarter recognition additional orders The that grew system for in to since revenue of existing upgrading came X the receipt older first robots. system last are increased and with current
geographies, harm and As the Johnson & weaknesses discussed the including greenfield for purchase shortages healthy and cycle of replacement more product X though delayed decisions. of fully historic on pipeline customers key our across last catheter a call, there Johnson, in active remains recurring ecosystem, Genesis our our
trial experience of positive partially submissions the helps. regulatory clinical recent observed in Our and our clinical MAGiC
catheter impacted by shortages, procedure is Our volumes. which recurring revenue impacting J&J's remains
in various availability catheters to of XXXX overall to geographies be revenue the recurring continue in J&J We with accounts, consistent but and XXXX. expect up see flare inconsistent
the EU-notified catheter driving success, regulatory of to We body both we pleased quarter. responsiveness Our key during the agencies. significant proprietary fronts. Stereotaxis' ablation remains are innovation FDA in was multiple first and making commercial strategy were substantial the submitted to progress with and
completeness In and, received of single of a shortly. received submission the did the responded of received questions not last intend those very and, question a round we Europe, following week, clinical respond we end follow-up question. check to our questions. to soon at application CE We after, concern, first shortly raise That and a
We questions biocompatibility the are though during that technical progress still and was year. on those last there note substantial topics awaiting review
the traditional convert our of MAGiC body U.S., to the into submission study along supplement broader leveraging bench through we and, a conversion initial is review, with took taking available coming the PMA from collect European place, appreciate and the enroll now of overall progressed and with them catheter excellent continued it. months who study, performance. responsiveness nature has the to working record on and for look a in MAGiC plan ensure depend with both to patients and the discussion, during In PMA. its MAGiC study in well FDA going the physicians for continue determined collaborative patients and additional data data.
Enrollment in forward regulators perfect We the reviewed the the and becomes That in to PMA to the preclinical the place Europe, collaborative the safety traditional
enhance development a technology. the of robot second accessibility the smaller major is self-shielding of effort innovation significantly Our our to
regulatory through of needed extensive working and for very well. majority the submission completed testing the We the tests robot performing are with methodically all successfully
the the the and regulatory in expect followed year. second of FDA submissions with by Europe this midyear, both to We United regulatory clearance continue in European quarter States expected clearance half
supply with to use robot enhanced in chain, prepare of the the and real-world the manufacturing, to Following the robot our installation we processes XXXX. current compatibility in for the a launch use, full X-rays of plan demonstrate year approval, reality commercial and various
of the the of that pace the of and to adoption. our and a scale reinforces robot as to demonstrations initial customers confidence physician robot Our more smaller significant improvement serve accessible a availability structural will
effort our ramp-up at robot's expected, the range a The guidewires slightly be bringing indications. guide on expand of value predicated to catheter robotically APT manufactured with submissions is acquisition. APT, in-house has of later of by the the of third broader year. the that manufacturing commercial with the catheters. in third expect beyond Our scope into development family we regulatory is slower guide a end is been we This delighted endovascular electrophysiology but guidewire project and than being of the quarter the to of The and are steered in availability
expect XXXX. catheter available to commercially in We early the be
their and begun training the of group have with anticipation and team. on robotic approximately In catheter partner, ablation and aspects approval our robotically MicroPort, a all responding the system as technology MicroPort of integration XXX is EP MicroPort body. clinical China's our sales summer launch, of ecosystem Genesis continues has for we team has of before program product the NMPA ramping navigated approval methodical mapping China, our key as regulatory training the from regulatory of in one-on-one members to commercial expect to submitted approval of this been up to year-end. provides all well questions its that and MicroPort
in regulatory await months the display. the submissions are couple being Synchrony lab later we as for Our operating should Synchrony-integrated and testing during digital features surgery quarter. effort release which time connectivity. regulatory limited launch cloud-based begin remains broad third formal is app of Sync incorporated last in platform a improvements key the our of additional with The ] innovation connectivity in room [
coming been venture our very early being While core to and a the positive, this business in substantial years. strategy, is has this feedback synergistic I and see can independent opportunistic a
will a technology event We showcase the future dedicate fully. to
provide These physicians attractive more profile. They with scale we leaps healthier experience and clinically, and forward revenue improve in meaningfully are the business and a provide ability cost and individually especially can we to our innovations, and each patients, commercially care combination, a strategically.
As and XXXX beyond. breakout these setting on ourselves puzzle together, multiple we pieces goal shots growth up key in come are with for
Stereotaxis team I the driving the are projects advance is what has want multiple parallel a forward unique accomplish, our in and lean none. of of to recognize ability impressive expertise small a to progress forward. to We innovation, to team our amazingly have It as fashion. that really work team breadth the been prudent this and able in capabilities financially the second quality
our the expertise of is it in-house clear capabilities coming strategize lack wave in becomes past the innovations several As look one devices. advancing develop gap the and disposal to our medical we reflect on and for years, of experience this forward interventional over years that
towards excited robot. a ideal with a Our that I'm manufacturing broad is be we future family eye partners APT that has the which of reliance worked capability. robust future, a contributing in for on driving very our are With joining various innovation and as work will Stereotaxis but manufacturing to and that contract interventional devices be of that and unlikely solution reasonable expertise
acquisition is strategic. Our of APT opportunistic, synergistic and
background, of made manually APT's by was differentiated, way using to a catheters respected steered that wanted diagnostic electrophysiologists Genesis. work were version highly By APT navigated with to robotically and I introduced
diagnostic mapping opportunity expertise robotically community We the impressed to to the catheter the with with their steered for work. of users. and of we quality catheter, unique, engage their collaborating first As develop robotic we APT's magnetically, began our high-density had team, were a
advanced include expanded guidance collaboration that vascular a our catheter. As we well, efforts to
that ensured we Earlier consider and appreciate emerged lot of APT strategic this interest Stereotaxis. to to prudent. agreement a and commercial into alignment opportunity acquisition a long-term year, perspective, of and able and on reach the we financially transaction from bringing was made An a sense were
Stereotaxis the a these high-quality From team, majority Stereotaxis perspective, of outside is for its to sales and people the practical calls enabling can catheters these meaningful complex in uses to the A the U.S. value complex and centers sales opener robotics. a The revenue substantial APT over requires of around a a the upon a currently the particularly for path in sales and most door the field adoption APT's practices perspective. distributors on to but come arrhythmias. commercial are on from pave the contribute the focused provide improving world at have our across catheters. team and in to treatment U.S. already synergies messaging U.S. who opportunity -- differentiated, distribute the sell dedicated XX agents and has focused with arrhythmias which from catheters and of serve skilled incremental as potential
post year to $X during first We in contribute acquisition. the expect APT annual million revenue approximately
accelerate how innovation From look APT's limiting. been expertise and amplify a and efforts earlier in-house across and will significantly to in mission. wave manufacturing robots welcome we expertise family perspective, Stereotaxis' a development capabilities catheter APT I I next the of lack of mentioned look strategic has team, their the of as devices and interventional to as develop team our contribution navigated a are forward endovascular members that core our by Stereotaxis to procedures. warmly range broader of
X and fully regulatory coming stock. transaction catheters, regulatory and over financial growth milestones. key milestones subject acquisition specific close and on milestones of customary will of commercial is catheters. expected considerations the applications, paid While upfront APT being closing and and the quarter, specific to on endovascular can adoption not revenue are in for out that terms years play majority conditions. steered be predicated are to The and the predicated is meeting meaningful electrophysiology disclosed, milestone the in robotically approvals third the The acquisition consideration Those both of include in
make call before I'll Kim? our well financial I'll which, will comments now over a results. the call commentary on the After few financial to who Q&A. hand as provide opening to Kim,
